mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor

Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the curr...

Full description

Saved in:
Bibliographic Details
Published inACS medicinal chemistry letters Vol. 13; no. 9; pp. 1379 - 1383
Main Authors Iskandar, Sabrina E., Bowers, Albert A.
Format Journal Article
LanguageEnglish
Published American Chemical Society 08.09.2022
Subjects
Viewpoint
proprotein convertase subtilisin/kexin type 9
macrocyclic peptides
mRNA display
hyper­chol­esterol­emia
noncanonical amino acids
peptide therapeutics
Online AccessGet full text

Cover

More Information
Summary:Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.2c00319